Citations

Clear

590 citation(s) found for "Ho, Ben".

DNTT-mediated DNA damage response drives inotuzumab ozogamicin resistance in B-cell acute lymphoblastic leukemia
Escherich, Carolin S. , Hsiao, Yu-Chih , Yang, Wenjian , Li, Yizhen , Reyes, Noemi , Walker, Megan, Budhraja, Amit , Bhatara, Sheetal , Paietta, Elisabeth , Konopleva, Marina , Litzow, Mark R. , Inaba, Hiroto , Opferman, Joseph T. , Loh, Mignon L. , Yu, Jiyang , Evans, William E. , Li, Zhenhua , Yang, Wenjian , Li, Yizhen , Bhatara, Sheetal , Konopleva, Marina , Litzow, Mark R. , Pui, Ching-Hon , Loh, Mignon L , Yu, Jiyang , Yang, Jun J.J. , Inaba, Hiroto , Escherich, Carolin , Moriyama, Takaya , Li, Zhenhua, Díaz-Flores, Ernesto , Stock, Wendy , Kornblau, Steven M. , O'Brien, Maureen Megan

Mayo Clinic

Blood | January 10, 2025 | Volume: 145 | Issue: 11 | Pages: 1182-1194

10.1182/blood.2024026085 | PMID 39791601 Get It

Abstract Inotuzumab ozogamicin (InO) is an antibody-calicheamicin conjugate with striking efficacy in B-cell acute lymphoblastic leukemia (B-ALL). However, there is wide interpatient variability in treatment response, and the genetic basis of this variation remains largely unknown. Using a genome-wide CRISPR screen, we discovered that the loss of DNA nucleotidylexotransferase (DNTT) is a primary driver of InO resistance. Mechanistically, the downregulation of DNTT attenuated InO–induced DNA damage response, cell cycle arrest, and mitochondrial apoptotic priming, thereby ultimately leading to leukemia resistance to InO. Ex vivo leukemia InO sensitivity was highly associated with DNTT expression in ALL blasts with substantial intraleukemia heterogeneity as revealed by single-cell RNA sequencing. Among patients with B-ALL enrolled in the Children's Oncology Group trial AALL1621, we observed consistent DNTT downregulation in residual blasts following InO treatment. The selection of DNTT-low blasts by InO therapy was also recapitulated in vivo using patient-derived xenograft models. Collectively, our data indicate that DNTT is a key regulator of calicheamicin response in leukemia and thus a potential biomarker for individualizing InO therapy in B-ALL.
Discovery of PRMT5 N-Terminal TIM Barrel Ligands from Machine-Learning-Based Virtual Screening
Shen, Zhihang , Seabra, Gustavo , Brant, Jason O. , Lewis, Ben , Li, Chenglong , Deleyrolle, Loic , Li, Chenglong , Shirlekar, Kalyanee , Deleyrolle, Loic P.

Mayo Clinic

ACS Omega | January 2, 2025 | Volume: 10 | Issue: 1 | Pages: 1156-1163

10.1021/acsomega.4c08661 | PMID 39829491 Get It

Gut Microbiome Modulation of Glutamate Dynamics: Implications for Brain Health and Neurotoxicity
Gruenbaum, Benjamin F. , Merchant, Kiran S. , Boyko, Matthew , Boyko, Matthew , Gruenbaum, Benjamin Fredrick , Merchant, Kiran S , Zlotnik, Alexander Anatolievich

Mayo Clinic

Nutrients | December 23, 2024 | Volume: 16 | Issue: 24 | Pages: 4405

10.3390/nu16244405 | PMID 39771027 Get It

The gut–brain axis plays an integral role in maintaining overall health, with growing evidence suggesting its impact on the development of various neuropsychiatric disorders, including depression. This review explores the complex relationship between gut microbiota and glutamate (Glu) regulation, highlighting its effect on brain health, particularly in the context of depression following certain neurological insults. We discuss how microbial populations can either facilitate or limit Glu uptake, influencing its bioavailability and predisposing to neuroinflammation and neurotoxicity. Additionally, we examine the role of gut metabolites and their influence on the blood–brain barrier and neurotransmitter systems involved in mood regulation. The therapeutic potential of microbiome-targeted interventions, such as fecal microbiota transplantation, is also highlighted. While much research has explored the role of Glu in major depressive disorders and other neurological diseases, the contribution of gut microbiota in post-neurological depression remains underexplored. Future research should focus on explaining the mechanisms linking the gut microbiota to neuropsychiatric outcomes, particularly in conditions such as post-stroke depression, post-traumatic brain-injury depression, and epilepsy-associated depression. Systematic reviews and human clinical studies are needed to establish causal relationships and assess the efficacy of microbiome-targeted therapies in improving the neuropsychiatric sequalae after neurological insults.
Utilization of Interval Throwing Programs: Analysis of Athletic Trainer, Physical Therapist, and Physician Perspectives
Sciascia, Aaron , Grantham, W. Jeffrey , Stone, Austin V. , Tremble, Corey, Uhl, Tim L. , Kibler, W. Ben, Uhl, Tim , Camp, Christopher L. , Sciascia, Aaron D. , Tremble, Corey S , Kibler, W. Ben

Mayo Clinic

Journal of Sport Rehabilitation | December 21, 2024 | Volume: 34 | Issue: 5 | Pages: 523-535

10.1123/jsr.2024-0171 | PMID 39708791 Get It

Context : A common component within rehabilitation recommendations for baseball pitchers is employment of an interval throwing program. However, there is a lack of a consistent set of advocated guidelines for program content and implementation for athletes at the professional and collegiate levels. Design : Cross-sectional study. Methods : A survey was developed to obtain clinician views regarding the composition and implementation of interval throwing programs for baseball pitchers. The survey was divided into demographic information and sections on criteria to begin throwing programs, frequency of throwing, soreness management, warm-up components, program components and regulation of a program, and criteria to achieve permitting live throwing. Clinicians including physicians, physical therapists, and certified athletic trainers who evaluate and treat musculoskeletal injuries among baseball pitchers at the professional-level and/or collegiate-level clinician received the survey. Responses were tabulated and compared between the professional-level clinician and collegiate-level clinician groups using chi-square analyses with statistical significance set at P ≤ .05. Results : The survey was completed by 166 clinicians (collegiate level = 81, professional-level clinician = 85). There were no statistical differences between groups for allowing warm-up throws, program regulation, maximum distance allowed, managing soreness, or criteria to achieve before permitting live throwing. Between-group differences included criteria to begin a program (≤.03), warm-up distance ( P ≤ .02), nonthrowing warm-up methods ( P ≤ .04), non-warm-up distance ( P ≤ .01), using ratings of perceived exertion ( P < .01), throwing frequency ( P < .01), and program components ( P ≤ .04). Conclusions : Responses appear to mirror interval throwing program designs previously reported in the literature but there are modifications and additions utilized by clinicians at different playing levels.
Revisiting medical oaths: how student-driven ethical codes reflect changing values
Stein, Michael, Gruenbaum, Shaun E. , Jotkowitz, Alan, Gruenbaum, Shaun Evan, Stein, Michael

Mayo Clinic

Journal of Medical Ethics | December 18, 2024 | Volume: 51 | Issue: 10 | Pages: 679-683

10.1136/jme-2024-110460 | PMID 39694800 Get It

Background Medical oaths and ethical codes play a crucial role in guiding physicians through their professional responsibilities. This study extends prior research on ethical codes created by students at the Medical School for International Health (MSIH) by analysing codes from the years 2007 to 2022. Objective The objective of this study is to evaluate changes in the ethical principles emphasised by MSIH students over time and to compare these with previous cohorts. Methods Ethical codes from MSIH classes (2007–2022) were analysed using the framework developed by Baker. This framework categorises oaths into four sections: preamble, covenant, code of duties to patients and peroration. The focus was primarily on the code of duties to patients. Quantitative analysis was used to assess the prevalence of specific ethical principles. Results The study found an increased emphasis on principles such as ‘respect for patients’ and ‘cultural competence/sensitivity’, while traditional values like ‘benevolence’ and ‘honesty’ were mentioned less frequently. New themes, including ‘patient autonomy’ and ‘cultural competence’, emerged, reflecting a shift towards patient-centred care and justice, though emerging issues like artificial intelligence ethics were not addressed. Conclusions MSIH students’ ethical codes have evolved to emphasise patient respect and cultural competence. The findings suggest a maturation in the ethical perspectives of medical students, though gaps remain in addressing contemporary challenges. Future studies should explore how ethical codes can incorporate emerging issues in healthcare.
Stretch & exercise education improves pain levels in under-resourced collegiate club lacrosse players
Gawrys, Steven P. , Wilson, Holly, Matthias, Alexander K., Roush, Andrew J. , VandeMerwe, David C., Parker, Lawsen M., Starr, Evan G. , Wong, Westin J. , Enslow, Ryan , Wilde, Ben, Zapata, Isain , Pickett, Brent, Wilson, Holly

Mayo Clinic

The Physician and Sportsmedicine | December 14, 2024 | Volume: 53 | Issue: 3 | Pages: 230-237

10.1080/00913847.2024.2443389 | PMID 39673554 Get It

Olfactory function is reduced in a subset of former elite American football players with traumatic encephalopathy syndrome
Braunecker, Ben J, Groh, Jenna R., Adler, Charles H. , Alosco, Michael L. , Tripodis, Yorghos , Balcer, Laura J. , Bernick, Charles , Banks, Sarah J. , Wethe, Jennifer V. , Palmisano, Joseph , Martin, Brett, Hartlage, Kaitlin , Geda, Yonas E. , Cummings, Jeffery L., Shenton, Martha E., Reiman, Eric M. , Braunecker, Ben J. , Tripodis, Yorghos , Adler, C H , Geda, Yonas E , Wethe, Jennifer V , Braunecker, Ben J. , Groh, Jenna R. , Dodick, David W. , Barr, William , Cantu, Robert C. , Katz, Douglas I. , Mez, Jesse , Shenton, M.E., Stern, Robert A.

Mayo Clinic

Chemical Senses | December 11, 2024 | Volume: 49 | Issue: No issue available | Pages: No page available

10.1093/chemse/bjae043 | PMID 39657828 Get It

Abstract Former American football players are at risk for developing traumatic encephalopathy syndrome (TES), the clinical disorder associated with neuropathologically diagnosed chronic traumatic encephalopathy (CTE). The objective of this study was to determine whether hyposmia is present in traumatic encephalopathy syndrome. The study included 119 former professional American football players, 60 former college football players, and 58 same-age asymptomatic unexposed men from the DIAGNOSE CTE Research Project. All subjects included in the analysis had completed the Brief Smell Identification Test (B-SIT). Traumatic encephalopathy syndrome and the level of CTE certainty were diagnosed using the 2021 NINDS consensus diagnostic criteria. TES is categorized antemortem by provisional levels of increasing CTE certainty: Suggestive, Possible, and Probable. Former players who had traumatic encephalopathy syndrome and Probable CTE had lower B-SIT scores than those with TES and Suggestive CTE. Hyposmia was more likely in the former players with TES who were either CTE Possible or Probable than in those who did not have TES or had TES but were less likely to have CTE, or CTE Suggestive. There was no difference in B-SIT scores between all former players versus unexposed men nor overall between the football players with and without TES. We conclude that lower B-SIT scores may be a clinical biomarker for underlying CTE in former American football players.
Targeting the PI3K/AKT Pathway and Fatty Acid Synthase in AL Amyloidosis: Mechanistic Insights and Therapeutic Implications
Zvida‐Bloch, Tal , Bender, Benjamin, Duek, Adrian , Leiba, Merav , Shpilberg, Ofer , Muchtar, Eli , Salmon‐Divon, Mali , Dispenzieri, Angela , Gatt, Moshe E. , Hershkovitz‐Rokah, Oshrat

Mayo Clinic

Blood | December 6, 2024 | Volume: 144 | Issue: Supplement 1 | Pages: 3288-3288

10.1182/blood-2024-206682 Get It

Background: Systemic light chain (AL) amyloidosis is a clonal plasma cell disorder characterized by the deposition of misfolded immunoglobulin light chain products in vital organs, leading to significant organ dysfunction. The molecular mechanisms underlying its pathogenesis remain incompletely elucidated. Identifying the molecular mechanisms and novel therapeutic targets is critical for improving treatment strategies and patient outcomes. Our previous research work identified that the PI3K/AKT signaling pathway is overexpressed in AL amyloidosis (Zvida et al., Blood, 2022, Fishov et al., Cancer Med., 2023). This pathway plays a critical role in regulating cellular metabolism. Specifically activated AKT can phosphorylate and regulate various target proteins involved in metabolic processes. One of the significant targets is fatty acid synthase (FASN), an enzyme responsible for the synthesis of fatty acids. AKT can enhance FASN expression and activity, thereby promoting lipid biosynthesis. Additionally, elevated FASN levels can drive inflammation through increased fatty acid synthesis, which activates inflammatory signaling pathways and enhances cytokine production (Acosta-Martinez et al.,IJMC, 2022). Elevated levels of FASN have been associated with hematological malignancies and cell survival (Vanauberg, et al., Oncogenesis, 2023). However, its role in AL amyloidosis is yet to be elucidated. Aim: To determine the role of FASN in the pathology and inflammatory response in AL amyloidosis, and to evaluate the potential of targeting FASN and the PI3K/AKT pathway for therapeutic intervention. Methods: We profiled FASN expression in CD138+ bone marrow (BM) samples from patients with AL amyloidosis (n=20), Multiple Myeloma (MM) (n=20), Monoclonal Gammopathy of Undetermined (MGUS) (n=8) and Healthy Controls (HC) (n=6), using qRT-PCR. To further explore the relationship between the PI3K/AKT pathway and FASN, we treated ALMC-1 cells with Capivasertib (an AKT inhibitor) and assessed FASN protein levels, cell proliferation by WST-1 assay, cell cycle distribution by flow cytometry, light chain secretion by ELISA, and expression of AKT and its downstream targets via western blot analysis. Furthermore, TVB-2640 (FASN inhibitor) was used to evaluate the cell response to FASN inhibition. Results: Our analysis revealed a significant upregulation of FASN in AL amyloidosis BM samples compared to MM, MGUS, and HCs. Capivasertib treatment resulted in a dose-dependent reduction in FASN protein levels. Additionally, Capivasertib treatment inhibited cell proliferation, induced G1 phase cell cycle arrest, reduced light chain secretion, and decreased AKT protein expression and its downstream targets p4EBP pS6 and pERK. Elevated levels of proinflammatory cytokines, including TNF and IP-10 (CXCL-10), were observed in AL amyloidosis serum samples, suggesting the involvement of immune mechanisms and the PI3K/AKT pathway, potentially induced by FASN. Finally, treatment with TVB-2640 reduced cell viability and decreased the protein expression of LIPIN-1, which is one of the key target genes regulated by FASN. Conclusions: Our findings highlight the significant upregulation of FASN in AL amyloidosis and its regulation by the PI3K/AKT pathway. The observed effects of Capivasertib on FASN expression and cell proliferation, along with the upregulation of inflammatory cytokines, underscore the potential for targeting the PI3K/AKT signaling pathway and FASN in developing more specific therapeutic strategies for AL amyloidosis.
Biological and Prognostic Subgroups of Plasmablastic Lymphoma Defined By EBV Status and MYC Rearrangement- an L.L.M.P.P. Study
Lytle, Andrew , Slack, Graham W. , Farinha, Pedro , Cook, James R. , Ott, G., Rosenwald, Andreas , Greiner, Timothy C. , Inghirami, Giorgio , Weisenburger, Dennis D., Chan, Wing C. , Beiske, Klaus , Fu, Kai , Lenz, Georg , Scott, David W. , Farinha, Pedro , Wong, Jasper , Frontzek, Fabian , Collinge, Brett , Hilton, Laura K. , Ben‐Neriah, Susana , Gerrie, Alina S. , Yang, Li , Kosnopfel, Corinna , Salaverría, Itziar , Campo, Elı́as , Amador, Catalina , Jaffe, Elaine S. , Raess, Philipp W. , Song, Joo Y. , Weisenburger, Dennis D. , Holte, Harald , Delabie, Jan , Pittaluga, Stefania , Feldman, Andrew L. , Savage, Kerry J. , Mungall, Andrew J. , Steidl, Christian , Rimsza, Lisa M. , Morin, Ryan D

Mayo Clinic

Blood | December 5, 2024 | Volume: 144 | Issue: Supplement 1 | Pages: 231-231

10.1182/blood-2024-208880 Get It

Introduction Plasmablastic lymphoma (PBL) is a rare aggressive subtype of lymphoma. It is more common in HIV positive patients, and is often associated with Epstein-Barr virus (EBV) and MYC rearrangements. PBL is characterized by markers of plasmacytic differentiation including CD138 and MUM1/IRF4, and loss of B-cell markers such as CD20, which suggests a cell of origin similar to that of multiple myeloma (MM) or activated B-cell-like (ABC) diffuse large B-cell lymphoma (DLBCL). The standard of care for PBL is CHOP-based chemotherapy but this is frequently not curative. Other than EBV-negative status, which defines a high-risk group, no other biological features have been discovered that are associated with outcomes. Methods Here, we provide a comprehensive analysis of the genomic and transcriptomic landscape of PBL using a collection of 176 exomes and genomes (n=55 new, contributed by Lymphoma/Leukemia Molecular Profiling Project [LLMPP] sites and centrally reviewed by the LLMPP pathology panel [WHO 2016]; n=121 previously published [PMID: 33225311, 33951889, 34465776, 34714908]), 65 transcriptomes (n=44 new; n=21 published) and 37 in situ single cell transcriptomic profiles (CosMx Spatial Molecular Imager) from archival diagnostic tissue biopsies. Somatic mutations (SNVs/Indels) were identified using an ensemble of four variant callers (Strelka2, Lofreq, Mutect2, SAGE). Salmon and DESeq2 were used to identify differentially expressed genes. This multi-omics dataset was compared to other known B-cell malignancies including 92 MM, 238 Burkitt lymphomas (BL), and 208 DLBCLs. Cell segmentation of the CosMx data was performed using Baysor and downstream analyses were conducted using the Seurat workflow. For functional validation, cell viability assays (CellTiter-Glo Luminescent Assay) were conducted in the PBL cell line, PBL-1, and 4 control DLBCL cell lines. Results Within the cohort, 63% (106/169) of primary PBL cases were EBV-positive (EBV+) and 57% (82/144) harbored MYC rearrangements (MYC+). When stratifying patients by EBV and MYC rearrangement status, mutations in different genes were enriched in each group: STAT3 occurred in 55% (29/53) of EBV+/MYC+ PBLs; NOTCH1 in 19% (7/36) of EBV+/MYC-; MYC in 24% (6/25) and TP53 in 40% (10/25) of EBV-/MYC+ tumors; TET2 was mutated in 38% (9/24) and KRAS in 25% (6/24) of EBV-/MYC- PBLs. EBV-/MYC+ tumors represented a subgroup of patients with dismal outcomes. The 2-year overall survival (OS) of these patients was 22% compared to 61%, 78%, and 54% of EBV+/MYC+, EBV+/MYC-, and EBV-/MYC- PBL patients, respectively (log-rank test p-adj. &lt; 0.05). Consistent with previous studies, we observed recurrent mutations affecting JAK-STAT (STAT3, SOCS1, SOCS3, DUSP2) in 41% of cases and RAS-RAF (NRAS, KRAS, BRAF) signaling in 38% of all PBLs. In contrast to ABC-DLBCL, very few mutations occurred in the NF-κB signalling pathway. Accordingly, PBL showed marked downregulation of genes involved in B-cell receptor and NF-κB signaling. Consistent with the lack of reliance on these pathways, functional analyses in PBL-1 showed resistance to treatment to ibrutinib as well as PI3K- and MALT1-inhibitors. Moreover, constitutive expression of the IκBα super-repressor did not affect viability of PBL-1 cells. In situ single cell transcriptomic data analyses showed a sparse tumor microenvironment (TME) in PBL, with the primary non-malignant cell types being, on average, 10% macrophages, 7% NK/T cells, and 4% stromal cells of all represented cell types. EBV+/MYC+ tumors displayed a more abundant immune cell population with higher levels of macrophages (median 12%) and NK/T cells (median 9%), whereas EBV-/MYC- tumors were composed of the lowest levels of immune cells (median 4% macrophages and 1% NK/T cells). With respect to malignant cell phenotypes, we noted a novel population of SPP1-expressing cells that were enriched in EBV+/MYC+ tumors and a population of CD44-expressing cells that were enriched in EBV+/MYC- tumors. Conclusion Here we present novel subgroups of PBL with unique biology and clinical outcomes. We show that PBL does not rely on B-cell receptor signaling, instead relying on potentially targetable vulnerabilities in JAK-STAT, NOTCH, and RAS-RAF signaling according to EBV positivity and MYC rearrangement status. Lastly, we provide insight into the TME of PBL and demonstrate a novel population of SPP1 and CD44 expressing malignant cells in EBV+ tumors.